SANTA CLARA, Calif. - HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company, has revealed new data indicating its artificial intelligence (AI) algorithms, when applied to vectorcardiography (VCG), significantly enhance the detection of atrial flutter compared to single-lead electrocardiograms (ECGs) commonly used in wearables like smartwatches. The findings were presented during the European Heart Rhythm Association conference in Berlin, Germany.
According to the study, the HeartBeam AI with VCG showed a 28% improvement in identifying atrial flutter cases, achieving a sensitivity of 91.0% versus 71.2% for single-lead ECG, while maintaining high specificity. This comparison highlights the potential limitations of current smartwatch technologies, which typically incorporate single-lead ECGs and may not detect a broad range of cardiac irregularities as effectively.
Atrial flutter, a type of arrhythmia, is generally diagnosed with a 12-lead ECG by healthcare professionals, a process not always feasible during a cardiac event. The HeartBeam AI technology, combined with VCG, aims to offer a comparable performance to the 12-lead ECG and bridges the gap in cardiac monitoring, particularly in settings where traditional methods are impractical.
HeartBeam's proprietary 3D vectorelectrocardiography (VECG) technology records the heart's electrical activity in three dimensions and synthesizes it into a 12-lead ECG. The company's upcoming HeartBeam AIMIGo™ device, a compact, portable monitor designed for patient use at home or on the go, is currently pending FDA review.
Dr. Vivek Reddy, who presented the data, emphasized the potential of VCG-based algorithms to exceed the arrhythmia detection capabilities of today's wearables. HeartBeam's CEO, Branislav Vajdic, PhD, expressed optimism about the AI program's ability to unlock new detection and prediction capabilities that could transform cardiac health management.
This report is based on a press release statement by HeartBeam, Inc.
InvestingPro Insights
HeartBeam, Inc. (NASDAQ:BEAT) is making waves with its innovative AI technology aimed at improving cardiac care, but what does the financial picture look like for investors? According to InvestingPro data, HeartBeam has a market capitalization of $56.61 million and is not profitable over the last twelve months as of Q4 2023, with a negative Price/Earnings (P/E) ratio of -3.87. The company's stock has experienced a 1-month price total return of 8.04%, showing some recent positive momentum.
Delving into the InvestingPro Tips, it's worth noting that HeartBeam holds more cash than debt on its balance sheet, which may provide some financial stability despite the company quickly burning through cash. Investors should also be aware that HeartBeam does not pay a dividend, which is common for companies focused on growth and reinvestment into their technology.
For those considering an investment in HeartBeam, the InvestingPro platform offers additional insights and tips to help make informed decisions. Currently, there are 6 more InvestingPro Tips available that could further guide potential investors. To access these tips and more detailed analytics, readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
As HeartBeam continues to develop its AI and VCG technologies, these financial metrics and expert tips from InvestingPro can help investors keep a pulse on the company's fiscal health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.